Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease
- PMID: 31507579
- PMCID: PMC6716072
- DOI: 10.3389/fmicb.2019.01977
Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease
Abstract
Treatment of Mycobacterium abscessus pulmonary infection requires long-term administration of multiple antibiotics. Little is known, however, about the impact of each antibiotic on treatment outcomes. A retrospective analysis was conducted to evaluate the efficacy and adverse effects of antibiotics administered in 244 cases of M. abscessus pulmonary disease. Only 110 (45.1%) patients met the criteria for treatment success. The efficacy of treating M. abscessus pulmonary disease continues to be unsatisfactory especially for infections involving M. abscessus subsp. abscessus. Treatment with drug combinations that included amikacin [adjusted odds ratio (AOR), 3.275; 95% confidence interval (CI), 1.221-8.788], imipenem (AOR, 2.078; 95% CI, 1.151-3.753), linezolid (AOR, 2.231; 95% CI, 1.078-4.616), or tigecycline (AOR, 2.040; 95% CI, 1.079-3.857) was successful. Adverse side effects affected the majority of patients (192/244, 78.7%). Severe effects that resulted in treatment modification included: gastrointestinal distress (29/60, 48.3%) mostly caused by tigecycline, ototoxicity (14/60, 23.3%) caused by amikacin; and myelosuppression (6/60, 10%) caused mainly by linezolid. In conclusion, the success rate of treatment of M. abscessus pulmonary disease is still unsatisfactory. The administration of amikacin, imipenem, linezolid, and tigecycline correlated with increased treatment success. Adverse side effects are common due to long-term, combination antibiotic therapy. Ototoxicity, gastrointestinal distress, and myelosuppression are the most severe.
Keywords: Mycobacterium abscessus; adverse effect; drug; efficacy; pulmonary disease.
Figures
Similar articles
-
M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis.Eur Respir J. 2019 Jul 11;54(1):1801991. doi: 10.1183/13993003.01991-2018. Print 2019 Jul. Eur Respir J. 2019. PMID: 30880280
-
Comparison of two-drug combinations, amikacin/tigecycline/imipenem and amikacin/tigecycline/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay.J Antibiot (Tokyo). 2021 Apr;74(4):285-290. doi: 10.1038/s41429-020-00392-0. Epub 2021 Jan 8. J Antibiot (Tokyo). 2021. PMID: 33420382 Free PMC article.
-
Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease.mSphere. 2023 Apr 20;8(2):e0066522. doi: 10.1128/msphere.00665-22. Epub 2023 Mar 13. mSphere. 2023. PMID: 36912629 Free PMC article.
-
Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence.Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01206-17. doi: 10.1128/AAC.01206-17. Print 2017 Nov. Antimicrob Agents Chemother. 2017. PMID: 28807911 Free PMC article.
-
Treatment of Mycobacterium abscessus Pulmonary Disease.Chest. 2022 Jan;161(1):64-75. doi: 10.1016/j.chest.2021.07.035. Epub 2021 Jul 24. Chest. 2022. PMID: 34314673 Review.
Cited by
-
AR-12 Exhibits Direct and Host-Targeted Antibacterial Activity toward Mycobacterium abscessus.Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00236-20. doi: 10.1128/AAC.00236-20. Print 2020 Jul 22. Antimicrob Agents Chemother. 2020. PMID: 32482678 Free PMC article.
-
PROTAC antibiotics: the time is now.Expert Opin Drug Discov. 2023 Apr;18(4):363-370. doi: 10.1080/17460441.2023.2178413. Epub 2023 Feb 21. Expert Opin Drug Discov. 2023. PMID: 37027333 Free PMC article.
-
Mixed infection of three nontuberculous mycobacteria species identified by metagenomic next-generation sequencing in a patient with peritoneal dialysis-associated peritonitis: a rare case report and literature review.BMC Nephrol. 2023 Apr 13;24(1):95. doi: 10.1186/s12882-023-03156-8. BMC Nephrol. 2023. PMID: 37055720 Free PMC article. Review.
-
The problem of Mycobacterium abscessus complex: multi-drug resistance, bacteriophage susceptibility and potential healthcare transmission.Clin Microbiol Infect. 2023 Oct;29(10):1335.e9-1335.e16. doi: 10.1016/j.cmi.2023.06.026. Epub 2023 Jun 24. Clin Microbiol Infect. 2023. PMID: 37364635 Free PMC article.
-
Targeting Intracellular Bacteria with Dual Drug-loaded Lactoferrin Nanoparticles.ACS Infect Dis. 2024 May 10;10(5):1696-1710. doi: 10.1021/acsinfecdis.4c00045. Epub 2024 Apr 5. ACS Infect Dis. 2024. PMID: 38577780 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous